Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab

Anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME) favorably affects diabetic retinopathy (DR) improvement and worsening. It is unknown whether these effects differ across anti-VEGF agents. To compare changes in DR severity during aflibercept, bevacizumab, o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JAMA ophthalmology Jg. 135; H. 6; S. 558
Hauptverfasser:	Bressler, Susan B, Liu, Danni, Glassman, Adam R, Blodi, Barbara A, Castellarin, Alessandro A, Jampol, Lee M, Kaufman, Paul L, Melia, Michele, Singh, Harinderjit, Wells, John A
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.06.2017
Schlagworte:	Angiogenesis Inhibitors - administration & dosage Bevacizumab - administration & dosage Diabetic Retinopathy - diagnosis Diabetic Retinopathy - drug therapy Diabetic Retinopathy - physiopathology Disease Progression Dose-Response Relationship, Drug Follow-Up Studies Humans Intravitreal Injections Ranibizumab - administration & dosage Receptors, Vascular Endothelial Growth Factor - administration & dosage Recombinant Fusion Proteins - administration & dosage Retina - pathology Retrospective Studies Severity of Illness Index Time Factors Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity
ISSN:	2168-6173, 2168-6173
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!